Status: Recruiting
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Participants needed: 132
Trial details
Phase: Phase 1, Phase 2Age: 2-24Biological sex: AllType: InterventionalSponsor: St. Jude Children's Research HospitalUpdated: Feb 4, 2026Locations: 1
Eligibility criteria
Participants with histologically confirmed or suspected low-grade glioma, includ... [+6]
Participants with known current retinal pathology that is consistent with or a p... [+101]